• NeOnc Technologies Holdings, Inc. (NTHI) announced on June 23, 2026, that the Abu Dhabi health authority granted IND approval for NEO100 for multiple adult and pediatric glioma protocols.
  • This approval expands the company's clinical footprint in the UAE and supports parallel development with ongoing U.S. trials.
  • Shares of NTHI are trading at $5.37 (5.03%) up in pre-market sessions.